WallStreetZenWallStreetZen

NASDAQ: LGVN
Longeveron Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LGVN

Based on 1 analyst offering 12 month price targets for Longeveron Inc

Min Forecast
$10.00+657.58%
Avg Forecast
$10.00+657.58%
Max Forecast
$10.00+657.58%

Should I buy or sell LGVN stock?

Based on 1 analyst offering ratings for Longeveron Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LGVN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates LGVN as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their LGVN stock forecasts and price targets.

LGVN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-21

1 of 1

Forecast return on equity

Is LGVN forecast to generate an efficient return?

Company
N/A
Industry
158.69%
Market
89.3%

Forecast return on assets

Is LGVN forecast to generate an efficient return on assets?

Company
N/A
Industry
40.47%

LGVN earnings per share forecast

What is LGVN's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.37
Avg 2 year Forecast
-$1.32

LGVN revenue forecast

What is LGVN's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$1.7M-23.78%
Avg 2 year Forecast
$3.0M+33.48%
LGVN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LGVN revenue growth forecast

How is LGVN forecast to perform vs Biotechnology companies and vs the US market?

Company
72.51%
Industry
56.87%
Market
9.9%
LGVN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LGVN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LGVN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LGVN$1.32$10.00+657.58%Buy
BLRX$4.43$19.00+328.89%Strong Buy
CALC$1.43$16.00+1,018.88%Buy
BCTX$2.96$32.00+981.08%Buy
GBIO$0.30$8.50+2,733.33%Strong Buy
View Top Biotech Stocks

Longeveron Stock Forecast FAQ

Is Longeveron Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LGVN) stock is to Buy LGVN stock.

Out of 1 analyst, 0 (0%) are recommending LGVN as a Strong Buy, 1 (100%) are recommending LGVN as a Buy, 0 (0%) are recommending LGVN as a Hold, 0 (0%) are recommending LGVN as a Sell, and 0 (0%) are recommending LGVN as a Strong Sell.

If you're new to stock investing, here's how to buy Longeveron stock.

What is LGVN's earnings growth forecast for 2025-2026?

(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.31%.

Longeveron's earnings in 2025 is -$25,574,000.On average, 3 Wall Street analysts forecast LGVN's earnings for 2025 to be -$20,513,219, with the lowest LGVN earnings forecast at -$22,213,773, and the highest LGVN earnings forecast at -$18,011,167.

In 2026, LGVN is forecast to generate -$19,812,284 in earnings, with the lowest earnings forecast at -$21,763,494 and the highest earnings forecast at -$17,861,074.

What is LGVN's revenue growth forecast for 2025-2026?

(NASDAQ: LGVN) Longeveron's forecast annual revenue growth rate of 72.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.9%.

Longeveron's revenue in 2025 is $2,225,000.On average, 3 Wall Street analysts forecast LGVN's revenue for 2025 to be $25,455,783, with the lowest LGVN revenue forecast at $24,014,890, and the highest LGVN revenue forecast at $28,217,495.

In 2026, LGVN is forecast to generate $44,577,639 in revenue, with the lowest revenue forecast at $29,118,054 and the highest revenue forecast at $60,037,224.

What is LGVN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: LGVN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 40.47%.

What is LGVN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LGVN price target, the average LGVN price target is $10.00, with the highest LGVN stock price forecast at $10.00 and the lowest LGVN stock price forecast at $10.00.

The Wall Street analyst predicted that Longeveron's share price could reach $10.00 by Mar 21, 2026. The average Longeveron stock price prediction forecasts a potential upside of 657.58% from the current LGVN share price of $1.32.

What is LGVN's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: LGVN) Longeveron's current Earnings Per Share (EPS) is -$2.42. On average, analysts forecast that LGVN's EPS will be -$1.37 for 2025, with the lowest EPS forecast at -$1.48, and the highest EPS forecast at -$1.20. In 2026, LGVN's EPS is forecast to hit -$1.32 (min: -$1.45, max: -$1.19).

What is LGVN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: LGVN) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.